[{"id":"3513fc32-93ba-4272-be45-5e294da2ba02","acronym":"","url":"https://clinicaltrials.gov/study/NCT03970252","created_at":"2024-05-07T20:27:15.331Z","updated_at":"2025-02-25T14:28:23.674Z","phase":"Phase 1","brief_title":"Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer","source_id_and_acronym":"NCT03970252","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" IFNG","pipe":" | ","alterations":" IFNG-L","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IFNG-L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • oxaliplatin • irinotecan • leucovorin calcium • fluorouracil topical"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 07/24/2019","start_date":" 07/24/2019","primary_txt":" Primary completion: 05/25/2024","primary_completion_date":" 05/25/2024","study_txt":" Completion: 05/25/2024","study_completion_date":" 05/25/2024","last_update_posted":"2024-08-09"}]